亚去势睾酮最低值与中高危局限期前列腺癌临床结局
研究纳入764例2000至2015年接受雄激素剥夺治疗联合根治性放疗的中高危局限期前列腺癌美国退伍军人,比较睾酮最低值<20 ng/dL与20-49 ng/dL两组。20-49 ng/dL组3个月放疗后PSA和2年PSA最低值更高,10年生化复发率和转移率更高,前列腺癌特异性死亡率有更差趋势但未达统计学显著。
要点
- 睾酮最低值20-49 ng/dL组较<20 ng/dL组3个月放疗后PSA更高(ß=0.16,95%CI 0.06-0.26,P=.001)。
- 20-49 ng/dL组10年生化复发率28.1% vs <20 ng/dL组18.3%,多变量分析SDHR 1.62(95%CI 1.07-2.45,P=.02)。
- 20-49 ng/dL组10年转移率12.9% vs <20 ng/dL组7.8%,SDHR 2.19(95%CI 1.21-3.94,P=.009)。
核心结论
- 在50 ng/dL以下进一步抑制血清睾酮与更好的PSA应答及更低的生化复发率和转移率相关。
研究设计与样本
- 回顾性队列研究,纳入764例2000至2015年接受雄激素剥夺治疗联合根治性放疗的中高危局限期前列腺癌美国退伍军人。
- 按持续促性腺激素释放激素激动剂治疗期间最低睾酮测量值分为<20 ng/dL组与20-49 ng/dL组。
- PSA应答采用多变量线性回归分析,长期临床结局采用Fine-Gray竞争风险回归分析。
主要发现
- 睾酮最低值20-49 ng/dL组较<20 ng/dL组3个月放疗后PSA更高(ß=0.16,95%CI 0.06-0.26,P=.001)。
- 20-49 ng/dL组较<20 ng/dL组2年PSA最低值更高(ß=0.12,95%CI 0.04-0.21,P=.005)。
- 20-49 ng/dL组10年生化复发率28.1% vs <20 ng/dL组18.3%,多变量分析SDHR 1.62(95%CI 1.07-2.45,P=.02)。
- 20-49 ng/dL组10年转移率12.9% vs <20 ng/dL组7.8%,多变量分析SDHR 2.19(95%CI 1.21-3.94,P=.009)。
- 20-49 ng/dL组前列腺癌特异性死亡率有更差趋势(SDHR 1.95,95%CI 0.90-4.22,P=.09),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: It is unclear if additional serum testosterone suppression below the castrate threshold of 50 ng/dL improves clinical outcomes in patients with localized prostate cancer undergoing definitive therapy. METHODS AND MATERIALS: We examined the association of subcastrate testosterone nadir with prostate-specific antigen (PSA) response and long-term clinical outcomes in 764 U.S. veterans with intermediate- or high-risk localized prostate cancer treated with androgen deprivation therapy and definitive radiation therapy from 2000 to 2015. Patients were categorized into testosterone nadir groups based on the minimum testosterone measurement during continuous gonadotropic-releasing hormone agonist therapy (<20 ng/dL vs 20-49 ng/dL). Outcomes included PSA response (3-month post-radiation therapy PSA and 2-year PSA nadir; multivariable linear regression) and long-term clinical outcomes (biochemical recurrence, metastasis, and prostate cancer-specific mortality; Fine-Gray competing risk regression). RESULTS: A testosterone nadir of 20 to 49 ng/dL was associated with higher 3-month post-radiation therapy PSA compared to <20 ng/dL (ß = 0.16, 95% confidence interval [CI], 0.06-0.26, P = .001) and higher 2-year PSA nadir (ß = 0.12, 95% CI, 0.04-0.21, P = .005). Compared to the <20-ng/dL group, the 20 to 49-ng/dL group showed higher 10-year biochemical recurrence rates (28.1% vs 18.3%) and metastasis rates (12.9% vs 7.8%) persisting on multivariable analyses (biochemical recurrence: sub-distribution hazard ratio [SDHR], 1.62 for 20-49 ng/dL, 95% CI, 1.07-2.45, P = .02; metastasis: SDHR, 2.19, 95% CI, 1.21-3.94, P = .009). There was a trend toward inferior prostate cancer-specific mortality for the 20 to 49-ng/dL group (SDHR, 1.95, 95% CI, 0.90-4.22, P = .09). CONCLUSIONS: Additional serum testosterone suppression below 50 ng/dL was associated with improved PSA responses and lower rates of biochemical recurrence and metastasis in this cohort of patients with localized prostate cancer.
引用
- Bryant AK, McKay RR, Kader AK, et al. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30543857. doi:10.1016/j.ijrobp.2018.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。